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ABSTRACT
Objectives: To assess whether in people with poorly
controlled type 2 diabetes (HbA1c>7.5%) improvement
in HbA1c varies by ethnic and social group.
Design: Prospective 2-year cohort of type 2 diabetes
treated in general practice.
Setting and participants: All patients with type 2
diabetes in 100 of the 101 general practices in two
London boroughs. The sample consisted of an
ethnically diverse group with uncontrolled type 2
diabetes aged 37–71 years in 2007 and with HbA1c
recording in 2008–2009.
Outcome measure: Change from baseline HbA1c in
2007 and achievement of HbA1c control in 2008 and
2009 were estimated for each ethnic, social and
treatment group using multilevel modelling.
Results: The sample consisted of 6104 people; 18%
were white, 63% south Asian, 16% black African/
Caribbean and 3% other ethnic groups. HbA1c was
lower after 1 and 2 years in all ethnic groups but south
Asian people received significantly less benefit from
each diabetes treatment. After adjustment, south Asian
people were found to have 0.14% less reduction in
HbA1c compared to white people (95% CI 0.04% to
0.24%) and white people were 1.6 (95% CI 1.2 to 2.0)
times more likely to achieve HbA1c controlled to 7.5%
or less relative to south Asian people. HbA1c reduction
and control in black African/Caribbean and white
people did not differ significantly. There was no
evidence that social deprivation influenced HbA1c
reduction or control in this cohort.
Conclusions: In all treatment groups, south Asian
people with poorly controlled diabetes are less likely to
achieve controlled HbA1c, with less reduction in mean
HbA1c than white or black African/Caribbean people.
INTRODUCTION
An estimated two million (4%) people in the
UK have type 2 diabetes. It is a leading cause
of cardiovascular and related morbidity
and reduces life expectancy by 10 years.1 2
Higher HbA1c values are associated with
greater mortality and morbidity.3 4
Ethnic and social differences in diabetes
prevalence are substantial and increasing
particularly among south Asian people in
whom onset is a decade earlier, with higher
levels of HbA1c and increased morbidity in
comparison with white people.1 5 In 2004,
initiatives to improve care targeted the most
socially disadvantaged ‘Spearhead’ Primary
Care Trusts (PCT). In addition national guid-
ance was supported by a national quality and
outcomes framework (QoF) with ﬁnancial
incentives to general practitioners who
achieved HbA1c levels controlled to 7.5% or
less.6 7 From 2004 to 2010 more intensive
drug treatment was associated with improved
HbA1c control in all ethnic groups, but dif-
ferences between ethnic groups persisted.8–13
The 2009 national UK diabetes audit recorded
70% of white people with controlled HbA1c
levels, compared to 58% of south Asian
people.1
ARTICLE SUMMARY
Article focus
▪ Variation in HbA1c improvement by ethnic and
social groups, in people with poorly controlled
type 2 diabetes (HbA1c>7.5%).
▪ HbA1c improvement with different types of dia-
betes treatment by the ethnic group.
Key messages
▪ South Asian people have less improvement in
HbA1c than white or black African/Caribbeans.
▪ This is true in all treatment categories whether
on metformin alone, combined oral or insulin.
Strengths and limitations of this study
▪ It is representative of people routinely cared for
by general practitioners in community settings.
▪ Duration of diabetes is an important influence on
HbA1c and treatment response with longer dur-
ation in South Asians. We were unable to reliably
ascertain duration of diabetes and cannot
confirm whether duration is the cause of our
findings.
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There have been no trials to evaluate whether diabetes
treatments to control HbA1c levels are variably effective
by ethnic and social group.14–16 We aimed to assess, if
improvement in HbA1c in people with poorly controlled
type 2 diabetes (HbA1c>7.5%) varies by ethnic and
social group using primary care data in an ethnically
diverse population.
METHODS
This study is based on the electronic medical records of
all 101 general practices in Newham and Tower Hamlets
PCT which serve 440 000 people. The same computer
system and prespeciﬁed codes for recording data are
used by all practitioners. The data were accessed via
EMIS web (www.emis-online.com) in August 2010.
Individual self-reported ethnicity was recorded by
general practices using the groups identiﬁed in the
2001 UK census and collapsed into four categories;
white (British, Irish and other white), south Asian
(Bangladeshi, Indian, Pakistani, other Asian and mixed
Asian), black African/Caribbean (African, Caribbean,
black British and mixed black) and other (any other
recorded ethnic group). This enabled comparison with
existing studies in the UK. Social deprivation was mea-
sured using the Townsend score, which is routinely avail-
able in these electronic medical records. This score is
derived from Census data on unemployment, car and
home ownership and overcrowding at lower superoutput
area level (approximately 400 households) linked to
individual patient postcode.17 18 The score indicates
the spectrum of deprivation within small geographical
areas where the most deprived are likely to be
unemployed, without a car and living in rented, over-
crowded accommodation.
Body mass index (BMI) and serum cholesterol were
estimated using the latest recording in 2007. The latest
HbA1c value and all diabetes prescriptions within each
annual 12 month period were recorded. Variables were
marked as missing if values lay outside speciﬁed limits.
Broadly speaking there are four clinical stages of treat-
ment to reduce HbA1c levels in patients with diabetes;
diet only, metformin, other oral hypoglycaemic medica-
tion with or without metformin and insulin alone
or in combination with oral hypoglycaemic agents. We
extracted all prescriptions during the study period for
the cohort. We categorised treatment as; ‘Metformin
Only’ if the patient received only metformin for the
whole study period, ‘Combined Oral’ if the patient
received any other oral hypoglycaemic either without or
in addition to metformin for the whole study period and
did not receive insulin; ‘Insulin’ if the patient received
insulin for the whole study period; ‘Metformin Only to
Combined Oral’ if the patient changed from Metformin
to Combined Oral over the study period; ‘Any to
Insulin’ if the patient changed from Metformin only, or
Combined Oral over the study period. We did not
include patients without any prescriptions in a given
year as we were unable to ascertain whether they had in
fact left the practice.
The sample was drawn from all individuals recorded
as having type 2 diabetes at the start of the observation
period in the 101 general practices, aged 37–71 years in
2007, who had uncontrolled diabetes (HbA1c>7.5%) in
2007 and who also had HbA1c recorded in 2008 and
2009. Patients were excluded if treatment was missing
during one or more years or treatment did not ﬁt in any
of the cohort treatment categories described. The lower
age limit excluded misclassiﬁed type 1 diabetes and
older ages were excluded because intensive treatment
may be clinically inappropriate.19 20
Typically the ‘Combined Oral’ treatment will consist
of either sulphonylurea alone, or one of the newer oral
agents—thiazolidinediones, insulin secretagogues,
dipeptidylpeptidase-4 inhibitors—alone, or in combin-
ation with the sulphonylurea. We considered ﬁve subcat-
egories for ‘Combined Oral’: ‘Sulphonylurea alone’ if
the patient received only sulphonylurea for the whole
study period, ‘New agent alone’ if the patient received
only new agents for the whole study period,
‘Sulphonylurea and new agent’ if the patient received
sulphonylurea and new agents for the whole study
period, ‘One to both’ if the patient begun on either sul-
phonylurea or new agents and their treatment was inten-
siﬁed to both treatments during the study; and ‘Other’
otherwise.
Diabetes duration at baseline was categorised as
‘0–2 years’ if the patient received their ﬁrst diabetes
diagnosis code between 2005 and 2007, and ‘>2 years’ if
they received their ﬁrst code prior to 2005. Exploratory
analysis indicated that these codes were unreliable to
estimate time-with-diabetes prior to 2004.
Two outcome measures were used to assess treatment
effectiveness; change from baseline (CfB) HbA1c and
HbA1c control. HbA1c values in 2007 were taken as the
baseline covariate values. Thus, a patient’s CfB HbA1c
for 2008 was their 2008 value minus their 2007 value;
CfB HbA1c 2009 was their 2009 value minus their 2007
HbA1c value. A patient was considered to achieve
HbA1c control in 2008 if their 2008 HbA1c value was
7.5% or less and in 2009 if their 2009 HbA1c value was
7.5% or less.
STATISTICAL ANALYSIS
Analysis was performed using Stata V.12.0 (www.stata.com).
Demographic statistics for each ethnic group were calcu-
lated. Data were structured with variation at four levels; the
lowest level was year, level 2 was person, level 3 was practice
and level 4 was PCT. A linear multilevel model was used to
estimate the CfB HbA1c in 2008 and 2009.21 A logistic
multilevel model was used to estimate the probability of
achieving HbA1c control in 2008 and 2009. These models
incorporated the structure of the data by including
random effects for person, practice and year. The models
were adjusted for baseline HbA1c (2007 HbA1c value),
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age, sex, year, BMI, serum cholesterol, cohort treatment,
diabetes duration, Townsend category and ethnic group as
these variables were considered likely to inﬂuence HbA1c
improvement. Patients with ‘Other’ ethnic groups
recorded were not included in the model construction as
they consisted of many different ethnic groups and were
small in number.
An ethnicity×treatment interaction was added to each
model to assess whether ethnicity was a factor in HbA1c
reduction and HbA1c control for each treatment. An
ethnicity×year interaction was added to the models to
assess if the difference in HbA1c reduction and achieve-
ment of HbA1c control between ethnic groups changed
between 1 and 2 years. An ethnicity× diabetes duration
interaction was added to the models to assess whether
the difference between ethnic groups in HbA1c reduc-
tion and achievement of HbA1c control varied between
the two duration categories. Signiﬁcance was set at the
5% level.
Exploratory analysis was conducted on the ‘Combined
Oral’ subcategories.
RESULTS
In August 2010, data were collected from 100 of the 101
practices in Tower Hamlets and Newham. One practice
declined participation. Over the 3 years of the study,
a total of 28 041 people in the study age range were
identiﬁed as having type 2 diabetes in 2007 and 17 670
(63%) had an HbA1c recording in 2007. Of these
17 670 people, 8864 (50%) had uncontrolled diabetes
(HbA1c>7.5%) of whom 42% were white, 50% were
black African/Caribbean and 53% were south Asian.
Among the 8864 uncontrolled patients, 6464 (73%) also
had HbA1c values in 2008 and 2009. Of those excluded
because of missing HbA1c records, 30% were white,
25% south Asian and 27% black African/Caribbean
people; 27–28% were in each social deprivation group.
Finally 207 (3%) people were excluded because they
had missing treatment information in one or more years
and 153 (2%) did not ﬁt into any of the cohort treat-
ment categories described in the methods.
The ﬁnal sample therefore consisted of 6104 (68.9%)
of the 8864 people with uncontrolled diabetes HbA1c
>7.5%. Of these, 6017 (99%) had ethnicity recorded,
6087 (>99%) people had Townsend score recorded. Age
and sex was recorded in everyone and serum cholesterol
in 95% and BMI in 94%. In total there were 1101 (18%)
white, 3785 (63%) south Asian, 993 (16%) black
African/Caribbean and 160 (3%) other ethnic groups
in the sample. Only 2% of people fell in the two least
deprived quintiles, so the least three quintiles were
combined and categorised as ‘Least’ deprived (N=1204,
20%), ‘High’ deprivation if they were in the most
deprived quintile (N=1858, 31%) and ‘Medium’’
(N=3025, 50%) otherwise.
Table 1A describes the variable mean or percentage in
each category for each demographic group. Table 1B
describes the HbA1c mean and proportion of HbA1c
control for each demographic group. Baseline HbA1c
and the diabetes duration distribution were similar
between ethnic groups. After 1 and 2 years mean HbA1c
decreased in each ethnic group but the mean reduction
in HbA1c from baseline was less in south Asian patients
than other ethnic groups and these patients had the
least chance of achieving HbA1c controlled to 7.5% or
less. A similar proportion of each ethnic group fell into
each deprivation category.
Altogether, 7% of patients remained on ‘Metformin
Only’ for the whole study, 46% on ‘Combined Oral’ and
33% on ‘Insulin’. Treatment intensity increased in 15%
of patients during the study. Despite similar baseline
HbA1c, treatment categories between ethnic groups
differed signiﬁcantly (p<0.001); there was a greater
Table 1A Patient characteristics
Demographic and clinical characteristics by ethnic group
Variable Category white South Asian Black All
N – 1101 3785 971 6104
% – 18 63 16 –
Mean age at baseline (years) – 60 56 58 57
Serum cholesterol (mmol/l) – 4.3 4.1 4.4 4.2
BMI – 34 28 31 29
Sex (%) Male 59 52 47 53
Townsend group (%) Least 19 19 20 20
Medium 52 48 54 50
High 29 33 26 31
Treatment group (%) Metformin Only 7 7 7 7
Combined Oral 35 50 44 46
Insulin 40 30 35 33
Metformin to Combined Oral 10 7 7 8
Any to Insulin 9 6 7 7
Diabetes duration 0–2 years 21 18 19 19
>2 years 79 82 81 81
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proportion of south Asian people on ‘Combined Oral
treatment’ 50% than white 35% or black African
Caribbean 44% and a greater proportion of south Asian
80% and black African/Caribbean people 79% started
and remained on more intensive treatment (either
Combined oral or insulin) than white 75%.
Fewer south Asian people, 36% started or changed to
insulin compared to black African/Caribbean 42% and
white people 49%. A subanalysis indicated white people
were signiﬁcantly more likely to increase their treatment
intensity 30%, than south Asian 19% and black people
22% (p<0.001).
Table 2A,B describe the statistical models to esti-
mate CfB HbA1c and HbA1c control. Person, practice
and PCT were all signiﬁcant (p<0.001) and were
included in the ﬁnal models. Baseline HbA1c, age,
serum cholesterol, ethnicity, sex and cohort treatment
had a signiﬁcant effect on CfB HbA1c and HbA1c
control. Townsend category and BMI were not signiﬁ-
cant but were retained in the models as variables of
Table 2A Statistical model parameter estimates
Linear multilevel regression model to estimate change from baseline HbA1c (%)
Variable Category
Effect on CfB
HbA1c % 95% CI
Category
p value
Variable
p value
Baseline HbA1c – −0.53 (−0.55 to −0.51) <0.001 <0.001
Age – −0.01 (−0.02 to −0.01) <0.001 <0.001
Serum cholesterol – 0.10 (0.07 to 0.13) <0.001 <0.001
BMI – 0.00 (−0.01 to 0.01) 0.747 0.747
Year (2008=Ref) 2009 0.11 (0.07 to 0.15) <0.001 <0.001
Sex (female=Ref) Male 0.15 (0.08 to 0.22) <0.001 <0.001
Ethnicity (white=Ref) South Asian 0.14 (0.04 to 0.24) 0.005 <0.001
black −0.02 (−0.14 to 0.09) 0.705
Townsend (least=Ref) Medium 0.07 (−0.03 to 0.16) 0.158 0.3013
High 0.08 (−0.03 to 0.19) 0.161
Treatment (Metformin Only=Ref) Combined Oral 0.54 (0.40 to 0.68) <0.001 <0.001
Insulin 0.98 (0.83 to 1.13) <0.001
Metformin to
Combined Oral
0.36 (0.19 to 0.54) <0.001
Any to Insulin 1.11 (0.92 to 1.30) <0.001
Diabetes duration (0–2 years=Ref) >2 years 0.30 (0.21 to 0.40) <0.001 <0.001
Table 1B
Changes in HbA1c over time
Variable Category
Baseline
HbA1c
2008 CfB
HbA1c
2009 CfB
HbA1c
Baseline
HbA1c control
2008 HbA1c
control
2009 HbA1c
control
Sex (%) Male 9.2 −0.3 −0.3 0 29 29
Female 9.1 −0.3 −0.3 0 32 32
Ethnicity White 9.2 −0.7 −0.6 0 33 34
South Asian 9.1 −0.5 −0.4 0 29 29
Black 9.3 −0.8 −0.7 0 33 33
Townsend group (%) Least 9.2 −0.4 −0.3 0 36 33
Medium 9.2 −0.3 −0.3 0 31 32
High 9.0 −0.3 −0.3 0 26 26
Treatment group (%) Metformin Only 8.5 −1.0 −0.9 0 62 64
Combined Oral 8.9 −0.6 −0.4 0 36 34
Insulin 9.5 −0.5 −0.4 0 18 18
Metformin to
Combined Oral
9.0 −0.8 −0.8 0 35 39
Any to Insulin 9.8 −0.5 −0.5 0 17 19
Diabetes duration 0–2 years 9.1 −1.0 −0.9 0 42 42
>2 years 9.1 −0.5 −0.4 0 28 27
All – 9.2 −0.6 −0.5 0 30 30
BMI, body mass index; CfB, change from baseline; HbA1c.
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interest. The ethnicity×treatment and ethnicity×year
interactions were not signiﬁcant and were not
included in either model.
In people with uncontrolled HbA1c at baseline, after
1 and 2 years on treatment; south Asian people had
0.15% less reduction in mean HbA1c than white people
(p=0.005) and white people were 1.6 times (p<0.001) as
likely to achieve HbA1c control relative to south Asian
people. White and black African/Caribbean people had
no signiﬁcant difference in CfB HbA1c (p=0.705) or
HbA1c control achievement (p=0.460). There was no
evidence that social deprivation affected HbA1c reduc-
tion or HbA1c control achievement.
The ethnicity×treatment interaction was not signiﬁ-
cant, indicating that in each of the different treatment
groups, south Asian people had the smallest reduction
in HbA1c and the lowest probability of achieving HbA1c
control after 1 and 2 years. This also indicates white
and black African/Caribbean people have a similar
response to each treatment. The ethnicity×diabetes
duration interaction was not signiﬁcant, indicating that
south Asian people have the smallest reduction in
HbA1c and probability of achieving HbA1c control
when their duration of diabetes is between 0 and 2 years
and more than 2 years.
Figure 1 illustrates that for an individual with HbA1c
9% at baseline on ‘Metformin Only’ and ‘Insulin’ treat-
ments, that south Asian people had the least reduction
in HbA1c for each treatment.
There was little variation in the distribution of sub-
categories in the ‘Combined Oral’ treatment between
ethnic groups (table 3). Most noticeably, white people
were the most likely to intensify 20%, followed by
black African/Caribbean people 18% and south Asian
people 17%.
DISCUSSION
This observational study is the ﬁrst to assess whether
HbA1c responds equally to different types of diabetes
treatment in different ethnic and social groups. We
found HbA1c improved in all ethnic groups over a
2- year period, but HbA1c improved less in south Asian
people for each treatment relative to other ethnic
groups. We found no association between social depriv-
ation and HbA1c improvement after adjustment for
other variables.
The interpretation of the model coefﬁcients in
tables 2A,B can be illustrated by considering two patients
similar for all variables except for treatment. One patient
is on ‘Metformin Only’ and the other on ‘Insulin’. In
2008, the patient on ‘Insulin’ will have their HbA1c
reduced by 1.11 less than the patient on ‘Metformin
Figure 1 Expected HbA1c for each ethnic group on
‘Metformin Only’ and ‘Insulin’ treatment.
Table 2B
Logistic multilevel regression model to estimate HbA1c control
Variable Category OR 95% CI OR
Category
p value
Variable
p value
Baseline HbA1c – 0.55 (0.51 to 0.59) <0.001 <0.001
Age – 1.03 (1.02 to 1.04) <0.001 <0.001
Serum cholesterol – 0.87 (0.81 to 0.94) 0.001 0.001
BMI – 1.01 (1 to 1.03) 0.132 0.132
Year (2008=Ref) 2009 0.95 (0.85 to 1.06) 0.395 0.395
Sex (female=Ref) Male 0.81 (0.69 to 0.96) 0.014 <0.001
Ethnicity (white=Ref) South Asian 0.64 (0.50 to 0.81) <0.001 <0.001
black 0.90 (0.68 to 1.19) 0.460
Townsend (least=Ref) Medium 0.94 (0.76 to 1.16) 0.535 0.207
High 0.81 (0.62 to 1.05) 0.118
Cohort Treatment (Metformin Only=Ref) Combined Oral 0.21 (0.15 to 0.28) <0.001 <0.001
Insulin 0.06 (0.04 to 0.08) <0.001
Metformin to Combined Oral 0.24 (0.16 to 0.35) <0.001
Any to Insulin 0.07 (0.04 to 0.11) <0.001
Diabetes duration (0–2 years=Ref) >2 years 0.54 (0.44 to 0.68) <0.001 <0.001
BMI, body mass index; HbA1c.
James GD, Baker P, Badrick E, et al. BMJ Open 2012;2:e001477. doi:10.1136/bmjopen-2012-001477 5
Type 2 diabetes: treatment, ethnic and social group influences on HbA1c
Only’ treatment. The same comparison in table 2B indi-
cates a patient on ‘Insulin’ treatment has an OR of 0.06
meaning that a patient on Metformin is 16.67 (1/0.06)
times as likely to achieve HbA1c control than a patient on
Insulin. However, this does not indicate that Metformin is
more effective at controlling HbA1c then Insulin. This
study is unable to compare the effectiveness of these
treatments as HbA1c levels in patients on insulin are
more difﬁcult to control as they are likely to have
increased duration of diabetes and other diabetes drugs
have failed to control their HbA1c levels.
Higher HbA1c in south Asians has been conﬁrmed in
most studies which also conﬁrm their higher intensity of
oral treatment and lower use of insulin.15 22–24 Poor
HbA1c control in African Americans has also been
reported in the USA, though our study found no such
disparity in black African/Caribbean people.14 16 25 26
Our study is unable to differentiate the reasons
why south Asian patients respond less favourably to treat-
ment. It could be lack of treatment efﬁcacy in these
patients. Alternatively it could be due to the duration of
diabetes where HbA1c control has been shown to deteri-
orate despite treatment in all categories over time.27
South Asian people have earlier onset of diabetes as
reﬂected in our study by the younger mean age; 56 years
in south Asians compared to 60 years in white and
58 years in black African/Caribbean people. At the start
of the study more black African/Caribbean 79% and
south Asian patients 80% were already on higher-
intensity treatment (either Combined oral or insulin)
than white patients 75%. During the study period a sig-
niﬁcantly higher proportion of white people (p<0.001)
increased their intensity of treatment than black
African/Caribbean or south Asian people and this may
also have contributed to less reduction in HbA1c in the
latter who were already on more intensive treatment.
Our study is large and included almost all those diag-
nosed with type 2 diabetes in the age range in a large
contiguous geographical area. It has high numbers of
people in each ethnic group allowing for precise com-
parisons between ethnic groups and the extent and
quality of ethnic group and social deprivation recording
was high. For all adjustment variables used, less than
10% of data was missing. All patients had longitudinal
HbA1c values allowing us to examine the change in
HbA1c over time.
The different ethnic groups had similar mean baseline
HbA1c suggesting diabetes severity was similar across
ethnic groups. HbA1c increases with duration of dia-
betes but information was limited as exploratory analysis
indicated that durations exceeding 2 years could not be
further categorised reliably. The inclusion of age and
treatment in the statistical models explains some but not
all of the effect of diabetes duration on HbA1c. Longer
diabetes duration could therefore be an explanation for
the observed ethnic group differences.
A limitation of the study was the exclusion of 31% of
those with uncontrolled diabetes because of missing
treatment or HbA1c records which may have introduced
bias. However, fewer south Asians were excluded for this
reason which suggests that as a group, they were more
likely to be more concordant with care. Selection bias
was an unlikely cause of the smaller reduction of HbA1c
in south Asian people in this study. Finally, there is no
evidence to suggest that south Asian people are less
likely to respond to change in lifestyle factors such as
diet or physical activity as compared with other ethnic
groups.
CONCLUSION
This study provides evidence that south Asian people
with poorly controlled type 2 diabetes are on higher-
intensity treatment than white or black African/
Caribbean people. Despite this, south Asians tended to
achieve less HbA1c reduction over time than other
ethnic groups from all types of diabetes treatment
whether this was metformin alone, combined oral treat-
ment or insulin alone or in combination. While the
reasons for this remain uncertain, this ﬁnding is relevant
to clinicians seeking to achieve HbA1c control below
7.5%, particularly in areas with large south Asian
populations.
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